Bivalirudin CAS:128270-60-0

Bivalirudin is primarily used for anticoagulant therapy in two Settings: in cardiac interventional therapy, such as coronary interventional surgery (PCI) and vascular stenting, and in the treatment of specific thrombotic diseases, such as acute coronary syndromes (ACS). Application of cardiac interventional therapy: Bivalirudin is widely used during cardiac interventional therapy (PCI), especially for those patients who require thrombosis risk management. The advantage of Bivalirudin over traditional heparin-based drugs is its rapid onset and predictable anticoagulant effect, and it does not require metabolism in the body and can be cleared by non-specific proteases in plasma. Treatment of acute Coronary Syndrome (ACS) : Bivalirudin is commonly used for continuous anticoagulant therapy in patients with acute coronary syndromes, especially in cases of non-ST elevation myocardial infarction (NSTEMI) and angina pectoris (UA). It can reduce the risk of thrombosis and improve the patient's prognosis. In these applications, the use of Bivalirudin is supported by clinical guidelines and has been validated in multiple clinical trials for safety and efficacy. However, for each patient, the choice of treatment and specific dosage needs to be determined based on their specific clinical condition and risk factors to ensure the best treatment outcome and safety.